share_log

Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est

フルジェントジェネティクスは、2024年度の調整EPSガイダンスを-0.30ドルから0.33ドルに引き上げ、-0.39ドルの見積もりに対して。売上ガイダンスは2億8000万ドルに対して2億8216万ドルの見積もりを確認

Benzinga ·  11/08 20:17

Outlook:

For the full year 2024, Fulgent expects:

  • Core Revenue of approximately $280 million
  • GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
  • Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
  • Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*

*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする